|View printer-friendly version|
|Array BioPharma Inc. Announces Filing of Registration Statement|
|FOR IMMEDIATE RELEASE Array BioPharma Inc. Announces Filing of Registration Statement Boulder, Colo. – (September 15, 2000) – Array BioPharma Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of common stock. The offering is being made through an underwriting group led by co-lead managers Lehman Brothers Inc. and Deutsche Banc Alex. Brown and co-manager Legg Mason Wood Walker, Incorporated. All of the shares registered (excluding certain of the shares issuable in the underwriters’ over-allotment option, if exercised) will be offered by Array. |
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.
When available, copies of the prospectus relating to the offering may be obtained from Lehman Brothers Inc., 3 World Financial Center, New York, New York 10285, 212-526-7000; Deutsche Banc Alex. Brown, One South Street, Baltimore, Maryland 21202, 410-727-1700; Legg Mason Wood Walker, Incorporated, 100 Light Street, Baltimore, Maryland 21202, 410-539-0000.
Array is a discovery research company creating drug candidates through innovations in chemistry. Array’s scientists provide premium drug discovery products and services to create, evaluate and optimize potential drug candidates in collaboration with pharmaceutical and biotechnology companies. Array’s information-based approach is designed to improve the efficiency of the drug discovery process and increase the quality of potential drug candidates. Array also applies its drug discovery capabilities internally for its own drug discovery programs. # # #